Report cover image

Urinary Tract Cancer Market: Current Analysis and Forecast (2022-2028)

Publisher UnivDatos Market Insights
Published Jan 12, 2022
Length 168 Pages
SKU # Univ17631773

Description

Urinary Tract Cancer Market: Current Analysis and Forecast (2022-2028)

The urinary tract cancer market is expected to witness a CAGR of around 18% during the forecast period. Urinary tract cancer is a type of cancer that affects the urethra, bladder, and renal pelvic. The tube that carries urine from the bladder to the outside of the body is affected by urethral cancer. Immunotherapy and chemotherapy are the two major procedures for the treatment of urinary tract cancer. The growth of the global market for urinary tract cancer is driven by the increasing number of cases of bladder cancer, the rise in the elderly population, and the number of bladder cancer research centers. However, the risk associated with the use of drugs employed in urinary tract cancer restrains the market growth. On the other hand, new opportunities will arise in the coming years as global healthcare expenditure rise. For instance, in 2020, the estimated number of new cases of bladder cancer was 573,278, and the number of new cases of prostate cancer was 1,414,259 for both sexes.

Furthermore, rising product development by the key market players also contributes to market growth. for instance, Balversa (erdafitinib) was approved by Janssen Pharmaceutical in April 2019 by the US Food and Drug Administration (FDA). Metastatic urothelial carcinoma (mUC), a type of bladder cancer, will be treated with this new drug.
  • Based on cancer type, the market is segmented into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer. Among them, the bladder cancer category is to witness a significant CAGR during the forecast period. This is mainly due to rising cases of bladder cancer globally due to high tobacco consumption. For instance, according to the World Cancer Research Fund International, bladder cancer is the 10th most common cancer worldwide. It is the 6th most common cancer in men and the 17th most common cancer in women. There were more than 573,000 new cases of bladder cancer in 2020.
  • On the basis of treatment type, the market is categorized into chemotherapy and immunotherapy. Among these, immunotherapy to hold a significant share of the market in 2020. Immunotherapy boosts our body's ability to fight cancer by encouraging the immune system to produce more immune cells that fight cancer. Moreover, recent clinical trials and drug approval will also contribute to the growth of the market during the forecast period. For instance, updated data from the global Phase 2 study (CORE1) of CG0070 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) were announced by CG Oncology.
  • Based on distribution channel, the urinary tract cancer market has been classified into retail pharmacy and online pharmacy. The retail pharmacy category is to witness higher adoption of urinary tract cancer treatment during the forecast period. This is mainly due to the rising number of hospitals & oncology centers, the numerous discounts offered by retail pharmacies, and the rising prevalence of cancer in the general population, the retail pharmacy category further drives market expansion.
  • For a better understanding of the market adoption of the urinary tract cancer industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the rising research and development initiatives, increasing incidents of bladder cancer coupled with the rising geriatric population. In addition, the increasing presence of major pharmaceutical companies in the region coupled with their increasing focus on the research and development of new drugs is further expected to propel the market growth.
  • Some of the major players operating in the market include F. Hoffmann-La Roche, AstraZeneca plc, Bristol-Myers Squibb, Merck & Co Inc., Johnson & Johnson, Eli Lilly and Co., GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi, and Astellas Pharma Inc.

Table of Contents

168 Pages
1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Urinary Tract Cancer Market
2.2. Research Methodology of the Urinary Tract Cancer Market
2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE URINARY TRACT CANCER MARKET
6 URINARY TRACT CANCER MARKET REVENUE, 2020-2028F
7 MARKET INSIGHTS BY CANCER TYPE
7.1. Bladder Cancer
7.2. Urethral Cancer
7.3. Ureteric and Renal Pelvic Cancer
8 MARKET INSIGHTS BY TREATMENT TYPE
8.1. Chemotherapy
8.2. Immunotherapy
9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL
9.1. Retail Pharmacy
9.2. Online Pharmacy
10 MARKET INSIGHTS BY REGION
10.1. North America
10.1.1. U.S.
10.1.2. Canada
10.1.3. Rest of North America
10.2. Europe
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Rest of Asia-Pacific
10.4. Rest of World
11 URINARY TRACT CANCER MARKET DYNAMICS
11.1. Market Drivers
11.2. Market Challenges
11.3. Impact Analysis
12 URINARY TRACT CANCER MARKET OPPORTUNITIES
13 URINARY TRACT CANCER MARKET TRENDS
14 DEMAND AND SUPPLY-SIDE ANALYSIS
14.1. Demand Side Analysis
14.2. Supply Side Analysis
15 VALUE CHAIN ANALYSIS
16 COMPETITIVE SCENARIO
16.1. Competitive Landscape
16.1.1. Porters Fiver Forces Analysis
17 COMPANY PROFILED
17.1. F. Hoffmann-La Roche
17.2. AstraZeneca plc
17.3. Bristol-Myers Squibb
17.4. Merck & Co Inc.
17.5. Johnson & Johnson
17.6. Eli Lilly and Co.
17.7. GlaxoSmithKline plc
17.8. Novartis International AG
17.9. Pfizer Inc.
17.10. Astellas Pharma Inc.
18 DISCLAIMER

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us